An accelerated dose-escalation study of FATE-NK100 for the treatment of advanced solid tumors

Trial Profile

An accelerated dose-escalation study of FATE-NK100 for the treatment of advanced solid tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs FATE NK100 (Primary) ; Cetuximab; Trastuzumab
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms DIMENSION
  • Most Recent Events

    • 19 May 2017 New trial record
    • 15 May 2017 According to a Fate Therapeutics media release, the US FDA cleared the company's IND application in May 2017 for the clinical investigation of FATE-NK100, including in combination with monoclonal antibody therapy, in subjects with advanced solid tumor malignancies.
    • 10 May 2017 According to a Fate Therapeutics media release, each of the three arms of the study will enroll in parallel utilizing accelerated dose-escalation, with each arm expected to include an expansion cohort of up to an additional twenty subjects at the maximum tolerated dose level. In addition, observation of a RECIST partial response or greater will enable additional expansion of up to ten subjects in that tumor type.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top